Showing 341-350 of 20873 results for "".
- Medication Adherence and Glycemic Control in Older Adults with Type 2 Diabeteshttps://reachmd.com/news/medication-adherence-and-glycemic-control-in-older-adults-with-type-2-diabetes/2474295/Research reveals a paradox in diabetes management for older patients. Despite consistently high medication adherence, many elderly individuals do not reach optimal glycemic control. This discrepancy is driven by complex treatment regimens, behavior
- AI-Driven Subclassification of Type 2 Diabetes Utilizing Continuous Glucose Monitoringhttps://reachmd.com/news/ai-driven-subclassification-type-2-diabetes-utilizing-continuous-glucose-monitoring/2470872/What's New A new AI-based tool developed at Stanford Medicine offers a promising method to improve diabetes classification by identifying distinct subtypes using continuous glucose monitors. Significance This advancement can significantly enhance per
- For Type 1 Diabetes Distress, Focus First on Managing Emotionshttps://reachmd.com/news/for-type-1-diabetes-distress-focus-first-on-managing-emotions/2467007/The most effective way to reduce the distress that comes with having diabetes – and improve glucose control – is to focus on managing the emotional strain of living with the condition, a new study of adults that was led by researchers at UC San Francisco has found.</
- FreeDM2 Trial Links Real-Time Cgm To Better HbA1c In Type 2 Diabeteshttps://reachmd.com/news/freedm2-trial-links-real-time-cgm-to-better-hba1c-in-type-2-diabetes/2486833/Key Takeaways Greater HbA1c reduction was reported with real-time CGM than with finger-prick monitoring at 16 and 32 weeks. The randomized comparison included 303 participants with type 2 diabetes treated with basal insulin plus SGLT2 inhibitors, GLP-1
- Revolutionizing Kidney Transplant Outcomes: The Role of Anti-Obesity Drugs in Type 2 Diabetes Patientshttps://reachmd.com/news/revolutionizing-kidney-transplant-outcomes-the-role-of-anti-obesity-drugs-in-type-2-diabetes-patients/2471494/Recent clinical observations indicate that integrating anti-obesity drugs may significantly improve outcomes for kidney transplant recipients with type 2 diabetes by reducing post-surgical complications including organ failure, inflammation, organ rejection, and early death
- GLP-1 Drugs: A Promising Therapeutic Approach for Kidney Transplant Recipients with Type 2 Diabeteshttps://reachmd.com/news/glp-1-drugs-a-promising-therapeutic-approach-for-kidney-transplant-recipients-with-type-2-diabetes/2471590/Recent investigations highlight emerging evidence that GLP-1 drugs, traditionally used for anti‐obesity and metabolic regulation, may also reduce organ failure rates and improve survival in kidney transplant recipients with type 2 diabetes. Expl
- GLP-1 Receptor Agonists: A New Frontier in Managing Cancer Risk for Type 2 Diabeteshttps://reachmd.com/news/glp-1-receptor-agonists-a-new-frontier-in-managing-cancer-risk-for-type-2-diabetes/2471579/A recent study published in JAMA Network Open has revealed that patients with type 2 diabetes treated with GLP-1 receptor agonists may experience a significantly reduced risk of developing hematologic cancers compared to those on traditional therapies such as insulin and me
- ‘Sweat, Spike, Solve’: Research Suggests a New Strategy for People with Type 1 Diabetes to Lower Blood Sugar After Exercisehttps://reachmd.com/news/sweat-spike-solve-research-suggests-a-new-strategy-for-people-with-type-1-diabetes-to-lower-blood-sugar-after-exercise/2468400/Adults with Type 1 diabetes should perform aerobic cooldowns to manage high blood sugar after intense exercise where glucose levels might rise, according to current guidelines for managing the disease. However, this recommendation has never been empirica
- Tirzepatide for Type 2 Diabetes Associated with Lower Risks for Mortality, Adverse Heart, Kidney Eventshttps://reachmd.com/news/tirzepatide-for-type-2-diabetes-associated-with-lower-risks-for-mortality-adverse-heart-kidney-events/2467776/by Elana Gotkine For patients with type 2 diabetes, treatment with tirzepatide (a dual glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonist) is associated with lower risks for all-cause mortality and adverse cardiovascular and kidney even
- Analysis Reveals the Global Burden of Type 1 Diabetes in Adults Aged 65 Years & Olderhttps://reachmd.com/news/analysis-reveals-the-global-burden-of-type-1-diabetes-in-adults-aged-65-years-older/2467078/The number of people aged 65 and older with type 1 diabetes increased from 1.3 million in 1990 to 3.7 million in 2019, while death rates fell 25% from 4.7 per 100,000 population in 1990 to 3.5 in 2019, finds an analysis of data from over 200 count